US 4129564A
· Wiechert et al.
· 1978
[cited by applicant]
US 5314506A
· Midler, Jr.
· 1994
[cited by applicant]
US 6787531B1
· Hilman et al.
· 2004
[cited by applicant]
US 7786101B2
· Mayerofer
· 2010
[cited by applicant]
US 9603860B2
· Perrin
· 2017
[cited by examiner]
US 20020132801A1
· Heil
· 2002
[cited by applicant]
US 20040087563A1
· Mayerhofer
· 2004
[cited by applicant]
US 20050220825A1
· Funke et al.
· 2005
[cited by applicant]
US 20060009428A1
· Grubb et al.
· 2006
[cited by applicant]
US 20060293295A1
· Strothmann et al.
· 2006
[cited by applicant]
US 20190269620A1
· Perrin et al.
· 2019
[cited by applicant]
US 20200054566A1
· Perrin et al.
· 2020
[cited by applicant]
US 20210128586A1
· Perrin et al.
· 2021
[cited by applicant]
DE 2652761A1
· 1978
[cited by applicant]
DE 3022337A1
· 1982
[cited by applicant]
EC SP077844
· 2007
[cited by applicant]
EP 0551700A1
· 1993
[cited by applicant]
EP 1214076B1
· 2002
[cited by applicant]
EP 1380301A1
· 2004
[cited by applicant]
EP 1611892A2
· 2006
[cited by applicant]
EP 1746101A1
· 2007
[cited by applicant]
JP 2010503632A
· 2010
[cited by applicant]
WO 9806738A1
· 1998
[cited by applicant]
WO 0115701A1
· 2001
[cited by applicant]
WO 0152857A1
· 2001
[cited by applicant]
WO 2005087194A1
· 2005
[cited by applicant]
WO 2005087199A2
· 2005
[cited by applicant]
WO 2005105103A2
· 2005
[cited by applicant]
WO 2006015956A1
· 2006
[cited by applicant]
WO 2006061309A1
· 2006
[cited by applicant]
WO 2006128907A2
· 2006
[cited by applicant]
WO 2006138503A2
· 2006
[cited by applicant]
WO 2008003432A1
· 2008
[cited by applicant]
WO 2008031631A2
· 2008
[cited by applicant]
WO 2009036999A1
· 2009
[cited by applicant]
WO 2009100871A2
· 2009
[cited by applicant]
WO 2009138224A1
· 2009
[cited by applicant]
WO 2010015298A2
· 2010
[cited by applicant]
WO 2010015713A1
· 2010
[cited by applicant]
WO 2012000981A1
· 2012
[cited by applicant]
Collier, CMAJ Jun. 11, 2013; 185(9): E385-E386.
[cited by examiner]
“Micronor 0.35mg Tablets (Ortho) Jan. 2, 1973 Approval [Contraception]: Medical Officers Review; Chemistry,” FOI Services, 37 pages, 1972.
[cited by applicant]
“Part 5: Pharmaceutical Manufacturing” & “Chapter 55: Pharmaceutical Necessities,” Remington: The Science and Practice of Pharmacy, 21st Edition, ed. Beringer et al., p. 880 & 1059-1086, 2005. (7 pages).
[cited by applicant]
“World Contraceptive Patterns 2013,” United Nations, Department of Economic and Social Affairs, Population Division, 2 pages, 2013.
[cited by applicant]
“Yaz® (drospirenone and ethinyl estradiol) Tablets,” Bayer HealthCare Pharmaceuticals, p. 1-45, 2010.
[cited by applicant]
Abdollahi et al., “Obesity: risk of venous thrombosis and the interaction coagulation factor levels and oral contraceptive use,” Thromb. Haemost. 89(3):493-498, 2003.
[cited by applicant]
Amy, “Contraception for women: an evidence based overview,” BMJ 339:563-568, 2009. (10 pages).
[cited by applicant]
Archer et al., “Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability,” Contraception 92:439-444, 2015.
[cited by applicant]
Arias, R.D. et al., Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg, Contraception 74:234-238, 2006.
[cited by applicant]
Blanco-Molina et al., “Progestin-only contraception and venous thromboembolism,” Thrombosis Research 129:e257-e262, 2012.
[cited by applicant]
Blode et al., “A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers,” The European Journal of Contraception and Reproductive Health Care 5:256-264, 20…
[cited by applicant]
Bühler, “Pharmaceutical Technology of BASF Excipients,” BASF: the Chemical Company, 3rd revised edition, p. 1-166, 2008.
[cited by applicant]
Casey et al., “Association of body mass index with removal of etonogestrel subdermal implant,” Contraception 87:370-374, 2013.
[cited by applicant]
Cedergren, “Maternal Morbid Obesity and the Risk of Adverse Pregnancy Outcome,” Obstet. Gynecol. 103(2):219-224, 2004.
[cited by applicant]
Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s), YAZTM/Drospirenone (DRSP) 3mg/Ethinyl Estradiol (EE) 0.02mg, Jun. 15, 2005.
[cited by applicant]
Centers for Disease Control and Prevention, “U.S. Medical Eligibility Criteria for Contraceptive Use,” MMWR Early Release 59:1-86, 2010.
[cited by applicant]
Collins et al., Hormonal Contraception without estrogens, Human Reproduction Update, 2003, 9(4), p. 373-386.
[cited by applicant]
Connor et al., “Determining Risk Between Depo-Provera Use and Increased Uterine Bleeding in Obese and Overweight Women,” J. Am. Board Fam. Pract. 15(1):7-10, 2002.
[cited by applicant]
Corrigan et al., “Some Aspects of the Influence of Formulation on the Bioavailability of Drugs from Solid Dosage Forms,” Irish Journal of Medical Science 143(1):197-207, 1974.
[cited by applicant]
Curtis, K.M. et al., Progestogen-only contraceptive use in obese women. Contraception 2009;80(4):346-354.
[cited by applicant]
Dhanjal, “Contraception in women with medical problems,” Obstetric Medicine 1:78-87, 2008.
[cited by applicant]
Dinger et al., “Oral contraceptive effectiveness according to body mass index, weight, age, and other factors,” Am. J. Obstet. Gynecol. 263:e1-.e9, 2009.
[cited by applicant]
Dragoman et al., “Contraceptive vaginal ring effectiveness is maintained during six weeks use: A prospective study of normal BMI and obese women,” Contraception 87(4):432-436, 2013.
[cited by applicant]
Fan et al., “Impact of polymers on dissolution performance of an amorphous gelleable drug from surface-coated beads,” Eur. J. Pharm. Sci. 37(1):1-10, 2009. (abstract only).
[cited by applicant]
Flegal et al., “Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010,” Journal of the American Medical Association 307(5):491-97, 2012.
[cited by applicant]
Fraser et al., “Depo-Provera use in an Australian metropolitan practice,”
[cited by applicant]
Golightly et al., “Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I).,” Med. Toxicol. Adverse Drug Exp. 3(2):128-165, 1988.
[cited by applicant]
Hampton et al., “Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives,” Contraception 77:415-419, 2008.
[cited by applicant]
Harel et al., “Adolescents' Reasons for and Experience After Discontinuation of the Long-Acting Contraceptives Depo-Provera and Norplant,” J. Adolesc. Health 19(2):118-123, 1996.
[cited by applicant]
Hedaya, “8.3.1 Convention Oral Formulations” & “8.3.1.1 Solutions,” Basic Pharmacokinetics, 2nd Edition, CRC Press Pharmacy Education Series, 2012. (3 pages).
[cited by applicant]
Hill, “Gynecology Case Challenge: Vaginal Bleeding in a Woman Taking an Injectable Contraceptive,” Medscape Women's Health 3(1), p. 1-9, 1998.
[cited by applicant]
Imaizumi et al., “Stability and Several Physical Properties of Amorphous and Crystalline Forms of Indomethacin,” Chem. Pharm. Bull. 28(9):2565-2569, 1980.
[cited by applicant]
In vivo Pharmacokinetic data submitted.
[cited by applicant]
International Search Report and Written Opinion, mailed Jan. 17, 2013, for International Application No. PCT/EP2011/060795, 6 pages.
[cited by applicant]
Kaunitz, “Injectable Depot Medroxyprogesterone Acetate Contraception: An Update for U.S. Clinicians,” Int. J. Fertil. 43(2):73-83, 1998.
[cited by applicant]
Keder et al., “Compliance with depot medroxyprogesterone acetate: A randomized, controlled trial of intensive reminders,” Am. J. Obstet. Gynecol. 179(3 Pt 1):583-585, 1998.
[cited by applicant]
Kirk et al., “Analysis of androgenic steroid Girard P hydrazones using multistage tandem mass spectrometry,” Rapid Communication in Mass Spectrometry 20:1247-1252, 2006.
[cited by applicant]
Krattenmacher, “Drospirenone: pharmacology and pharmacokinetics of a unique progestogen,” Contraception 62:29-38, 2000.
[cited by applicant]
Lidegaard et al., “Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study,” BMJ 343(d6423):1-15, 2011.
[cited by applicant]
Mantha et al., “Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis,” BMJ 345(e4944):1-10, 2012.
[cited by applicant]
Murthy, “Obesity and Contraception: Emerging Issues,” Semin. Reprod. Med. 28(2):156-163, 2010.
[cited by applicant]
Niazi, Handbook of Pharmaceutical Manufacturing Formulations: Compressed Solid Products, vol. One, Second Edition, Informa Healthcare USA, Inc., New York, NY, p. 1-2738, 2009.
[cited by applicant]
Nutley et al., “Treatment of bleeding problems associated with progestin-only contraceptives: survey results,” Adv. Contracept. 13(4):419-28, 1997.
[cited by applicant]
O'Neil et al., The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals,14th edition, Merck & Co., Inc., Whitehouse Station, NJ, USA, p. 585, 2006.
[cited by applicant]
OECD/European Union, “Overweight and obesity among adults,” Health at a Glance: Europe 2014, OECD Publishing, Paris, FR, p. 56-57, 2014.
[cited by applicant]
Patel et al., “An overview of size reduction technologies in the field of pharmaceutical manufacturing,” Asian Journal of Pharmaceutics, p. 216-220, 2008.
[cited by applicant]
Pomp et al., “Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations,” Br. J. Haematol. 139:289-296, 2007.
[cited by applicant]
Puthli et al., “Formulation and Performance Characterization of Radio-sterilized “Progestin-only” Microparticles Intended for Contraception,” AAPS PharmSciTech 10(2):443-452, 2009.
[cited by applicant]
Reply to Oppositions against EP 1 380 301 B1 submitted on May 28, 2010.
[cited by applicant]
Rosenbaum et al., “Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol,” The European Journal of Contraception and Reproductive Health Care 5:16-24, 2000.
[cited by applicant]
Rosenberg et al., “Unintended Pregnancies and Use, Misuse and Discontinuation of Oral Contraceptives,” J. Reprod. Med. 40(5);355-360, 1995.
[cited by applicant]
Rosenberg, “Weight Change With Oral Contraceptive Use and During the Menstrual Cycle: Results of Daily Measurements,” Contraception 58:345-349, 1998.
[cited by applicant]
Rowe et al., Handbook of Pharmaceutical Excipients, Sixth Edition, Pharmaceutical Press, London, UK, p. 1-917, 2009.
[cited by applicant]
Sansom, Aust Prescr 1999;22:88-30 Aug. 1, 1999 (Year: 1999).
[cited by applicant]
Sedgh et al., “Intended and Unintended Pregnancies Worldwide in 2012 and Recent Trends,” Studies in Family Planning 45(3):301-314, 2014.
[cited by applicant]
Shigetoh et al., “Higher Heart Rate May Predispose to Obesity and Diabetes Mellitus: 20-Year Prospective Study in a General Population,” Am. J. Hypertension 22(2):151-155, 2009.
[cited by applicant]
Sitruk-Ware, “New progestagens for contraceptive use,” Human Reproduction Update 12(2):169-178, 2006.
[cited by applicant]
Spence et al., “Increased Dissolution Rate and Bioavailability Through Comicronization with Microcrystalline Cellulose,” Pharmaceutical Development and Technology 10:451-460, 2005.
[cited by applicant]
World Health Organization, Medical eligibility criteria for contraceptive use: 4th edition, 2009, WHO Press, Geneva, Switzerland, 129 pages, 2010.
[cited by applicant]
Zhang et al., “Effect of Diluents on Tablet Integrity and Controlled Drug Release,” Drug Development and Industrial Pharmacy 26(7):761-765, 2000.
[cited by applicant]